4D pharma Announces Completion of Merger With Longevity Acquisition Corporation
March 22 2021 - 2:00AM
Business Wire
Provides update on Nasdaq trading
4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or
the "Company"), a pharmaceutical company leading the development of
Live Biotherapeutic products (LBPs) - a novel class of drug derived
from the microbiome - today announced completion of its merger
(“the Merger”) with Longevity Acquisition Corporation
("Longevity")(Nasdaq: LOAC).
4D pharma American Depositary Shares (“ADSs”) are expected to
begin trading today on the Nasdaq Global Market under the ticker
symbol ‘LBPS.’
Warrants of Longevity assumed by 4D pharma in the Merger are
currently expected to begin trading on Nasdaq under the ticker
symbol ‘LBPSW’ tomorrow, Tuesday, March 23, 2021. Longevity units
are expected to be separated and holders thereof are expected
receive 4D pharma ADSs and warrants in exchange at the same time as
the warrants begin trading.
As a result of the Merger, Longevity shares, warrants, rights
and units ceased trading on Nasdaq on Friday, March 19, 2021.
4D pharma ordinary shares continue to be admitted to trading on
the London Stock Exchange’s AIM market under the ticker symbol
‘DDDD.’
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx®, that rationally identifies Live Biotherapeutics based on
a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in
patients hospitalized with COVID-19, and Blautix® in Irritable
Bowel Syndrome (IBS) which has completed a successful Phase II
trial. Preclinical-stage programs include candidates for CNS
disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com.
Forward-Looking Statements
This announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this announcement, including without limitation statements
regarding trading in ADSs and warrants and the separation of
Longevity units, are forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as
amended (the "Securities Act"), and Section 21E of the United
States Securities Exchange Act of 1934, as amended (the "Exchange
Act"). Forward-looking statements are often identified by the words
"believe," "expect," "anticipate," "plan," "intend," "foresee,"
"should," "would," "could," "may," "estimate," "outlook" and
similar expressions, including the negative thereof. The absence of
these words, however, does not mean that the statements are not
forward-looking. These forward-looking statements are based on the
Company's current expectations, beliefs and assumptions concerning
future developments and business conditions and their potential
effect on the Company. While management believes that these
forward-looking statements are reasonable as and when made, there
can be no assurance that future developments affecting the Company
will be those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties, some of which are significant
or beyond its control, and assumptions that could cause actual
results to differ materially from the Company's historical
experience and its present expectations or projections. The
foregoing factors and the other risks and uncertainties that could
cause actual results to differ materially include potential delays
in the commencement of trading Company ADSs and warrants and those
additional risks and uncertainties described the documents filed by
the Company with the US Securities and Exchange Commission (“SEC”),
all of which should be carefully considered. The Company wishes to
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date hereof. The Company
undertakes no obligation to publicly update or revise any of its
forward-looking statements after the date they are made, whether as
a result of new information, future events or otherwise, except to
the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210322005221/en/
4D pharma Investor Relations: ir@4dpharmaplc.com
Stern Investor Relations, Inc. Julie Seidel
+1-212-362-1200 Julie.seidel@sternir.com
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024